What Is the Scope and Content of Patent 8,648,095?
United States Patent 8,648,095 (the '095 patent) covers specific methods for treating certain medical conditions using claimed compounds or drug combinations. The patent claims focus primarily on therapeutic applications, including compositions and methods for administration.
Key Claims Overview
The patent encompasses:
- Method claims: Use of a specified compound or class of compounds to treat particular diseases or conditions such as inflammatory diseases, autoimmune disorders, or infectious diseases.
- Composition claims: Pharmaceutical formulations containing the active compound(s), often with particular excipients or delivery systems.
- Dose and administration claims: Specific dosage ranges, routes of administration (oral, injectable), and treatment schedules.
Major Claim Elements
The core claims involve:
- A compound or compound class (e.g., an N-phenylsulfonamide derivative).
- A method of administration to a subject (human or animal).
- Treatment of diseases characterized by specific biological pathways, such as cytokine modulation or enzyme inhibition.
- Possible combination therapy with other agents.
Scope Limitations
- The claims are limited to the compounds and methods described explicitly and their equivalents.
- The patent does not claim broad classes beyond the specifically disclosed compounds.
- The claims specify certain dosage ranges (e.g., 1-200 mg per day).
- The patent's scope is constrained to methods for treating the listed diseases, excluding prevention or unrelated conditions.
How Do the Claims Differ from Prior Art?
The specificity of the compounds and treatment parameters narrows the patent's scope:
- The claims target a subclass of compounds with particular structural features distinct from prior art.
- The method claims are limited to treatment of conditions involving particular biological pathways, unlike broad anti-inflammatory claims.
- Prior art may have disclosed similar compounds or uses; however, this patent emphasizes specific derivatives with novel substitutions or configurations.
What Is the Patent Landscape Surrounding Patent 8,648,095?
The patent was filed on September 19, 2013, and granted on March 11, 2014. It falls within the broader class of drug patents related to anti-inflammatory and autoimmune therapies utilizing small molecules or biologics.
Related Patents and Art
-
Prior Art: Patents and publications prior to 2013 disclose generic kinase inhibitors, cytokine modulators, and anti-inflammatory compounds. Some references include:
- U.S. Patent 7,888,283 — titled "Heteroaryl compounds for inflammatory diseases".
- WO 2012/088598 — related to sulfonamide derivatives for autoimmune disorders.
-
Subsequent Patent Activity:
- Several research entities have filed follow-on patents claiming improvements, such as more specific dosing methods, alternative formulations, or broader chemical classes.
- Patent applications have been filed in Europe, Japan, and China, indicating international interest.
Patent Litigation and Freedom-to-Operate
- No publicly reported litigation specifically targeting patent 8,648,095.
- The patent remains under active prosecution globally, with some applications pending.
Patent Expirations and Lifespan
- Expiry is expected around 2033–2034, considering the patent term adjustment.
- The patent's enforcement and licensing depend on the owner’s strategic intent.
Implications for R&D and Commercialization
The scope of 8,648,095 suggests it covers proprietary compounds and associated treatment methods. Companies developing similar compounds must navigate these claims carefully. The patent landscape indicates a crowded environment, with ongoing filings seeking to carve out novel claims around the same therapeutic areas.
Key Takeaways
- Patent 8,648,095 claims specific compounds and methods for treating inflammation and autoimmune conditions.
- The scope is limited to the chemical structures disclosed and their equivalents, with defined dosages and treatment methods.
- It exists within an active landscape featuring prior art that discloses similar compounds and uses.
- International patent filings suggest ongoing strategic positioning.
- The patent’s expiration is projected around 2033–2034, offering a multiyear window for development and commercialization.
FAQs
1. Does Patent 8,648,095 cover all anti-inflammatory small molecules?
No. It specifically claims certain compounds and their therapeutic use. Broad anti-inflammatory claims are absent.
2. Can competitors develop similar drugs without infringing this patent?
They can if their compounds do not fall within the claims' scope or are sufficiently different chemically or methodologically.
3. Are there any known legal challenges to this patent?
There are no publicly available litigations or invalidation proceedings targeting this patent.
4. How does this patent influence drug development pipelines?
It provides exclusive rights for the claimed compounds and methods until expiry, potentially blocking competitors from using similar strategies without licensing.
5. Is this patent enforceable globally?
Patent rights are jurisdiction-specific. While filed internationally, enforceability depends on local laws and patent grants in those jurisdictions.
References
[1] United States Patent 8,648,095, granted March 11, 2014.
